Fig. 1.

Cisplatin-resistant tumor samples express higher levels of BCL2 antagonist of cell death (BAD) pathway kinases and lower levels of BAD pathway phosphatases. Protein levels of the BAD pathway cyclin dependent kinase 1 (CDK1) (A) and protein phosphatase 2C (PP2C) (B) were evaluated by immunofluorescence in 64 primary ovarian cancer samples from tumors that demonstrated a complete response (CR, 41) or incomplete response (IR, 23) to primary platinum therapy. Error bars depict the standard error of the mean.